ライフサイエンスコーパス: T. vaginalis

1 T. vaginalis adhered to hVECs and produced severe cytoto

2 T. vaginalis and Tetratrichomonas gallinarum (both repre

3 T. vaginalis ASR is an increasingly utilized assay that

4 T. vaginalis detection rate in males was 6.6%, with no d

5 T. vaginalis DNA was stable in specimens stored without

6 T. vaginalis extract was subjected to hydrophobic chroma

7 T. vaginalis has the coding capacity to produce an activ

8 T. vaginalis HPP forms an approximately 100 kDa homodime

9 T. vaginalis infection is strongly associated with an in

10 T. vaginalis infection was identified in 6.0% (16/268) o

11 T. vaginalis is the most common sexually transmitted inf

12 T. vaginalis may alter the vaginal microbiota in a manne

13 T. vaginalis may be endemic in this community of African

14 T. vaginalis PNP thus belongs to the family of bacterial

15 T. vaginalis prevalence by culture (InPouch; Biomed) was

16 T. vaginalis prevalence differed by race/ethnicity, with

17 T. vaginalis prevalence ranged from 5.4% in family plann

18 T. vaginalis research entered the age of genomics with t

19 T. vaginalis was detected more often in men with wet-mou

20 T. vaginalis was more prevalent than C. trachomatis or N

21 T. vaginalis was most prevalent in women who were 36 to

22 T. vaginalis was the predominant sexually transmitted ag

23 is study, we examined the propensities of 26 T. vaginalis strains to bind to and lyse prostate (BPH-1

24 Vaginal samples from 30 T. vaginalis-infected women were matched by Nugent score

25 ere matched by Nugent score to those from 30 T. vaginalis-uninfected women.

26 Of 355 T. vaginalis isolates tested for TVV, T. vaginalis isola

27 nts, 858 pharyngeal specimens yielded a 2.9% T. vaginalis detection rate compared with 2.1% for N. go

28 A T. vaginalis cDNA expression library was screened with p

29 The SLPI level was reduced by >50% in a T. vaginalis load-dependent manner.

30 lment visits of 355 women participating in a T. vaginalis treatment trial in Birmingham, Alabama, wer

31 lated in vitro by the catalytic subunit of a T. vaginalis protein kinase A, TvPKAc.

32 The average age of a T. vaginalis-infected male (39.9 years) was significantl

33 kely as women with fewer partners to acquire T. vaginalis (hazard ratio, 4.3; 95% CI, 2.0-9.4).

34 acquired N. gonorrhoeae, and 12.8% acquired T. vaginalis); among 1183 men, 14.7% had 1 or more new i

35 tection of T. vaginalis was developed to add T. vaginalis infection to the growing list of STDs that

36 health care system was performed to address T. vaginalis prevalence in males.

37 s a potential chemotherapeutic agent against T. vaginalis.

38 rt the potential for a human vaccine against T. vaginalis infection that could also influence the inc

39 The aggregate T. vaginalis detection rate trended higher than that of

40 All T. vaginalis pharyngeal detections were confirmed by TMA

41 second ATV TMA assay, utilizing an alternate T. vaginalis primer and probe set, was performed on all

42 nin-labeled ELISA for detection of amplified T. vaginalis DNA from urine, the sensitivity and specifi

43 ), C. trachomatis (AOR, 1.43; P = .247), and T. vaginalis (AOR, 1.60; P = .120) independently increas

44 rachomatis, 11.6%; N. gonorrhoeae, 2.4%; and T. vaginalis, 1.7%.

45 The observation that the two diplomonads and T. vaginalis share the same unusual GK and GPI is consis

46 nt with oral metronidazole is effective, and T. vaginalis DNA disappears rapidly after treatment.

47 The M. genitalium and T. vaginalis detection rates among 755 patients at urban

48 ificantly higher than the N. gonorrhoeae and T. vaginalis infection rates.

49 mens for C. trachomatis, N. gonorrhoeae, and T. vaginalis TMA screening.

50 italium, C. trachomatis, N. gonorrhoeae, and T. vaginalis were 100, 70, 67, and 20%, respectively.

51 o detect C. trachomatis, N. gonorrhoeae, and T. vaginalis).

52 inal microbiota in T. vaginalis-infected and T. vaginalis-uninfected patients among women with normal

53 (CRS) comprised of wet-mount microscopy and T. vaginalis culture.

54 C. trachomatis and T. vaginalis infection increase the susceptibility to SH

55 n due to N. gonorrhoeae, C. trachomatis, and T. vaginalis were 3.48, 4.55, and 1.32 cases per 100 per

56 Aptima T. vaginalis assay performance was determined for each s

57 Aptima T. vaginalis clinical sensitivity and specificity were,

58 Aptima T. vaginalis performance levels were similar in asymptom

59 ated the performance of the automated Aptima T. vaginalis assay for detecting T. vaginalis in 1,025 a

60 hybridization assay to the Gen-Probe Aptima T. vaginalis (ATV) transcription-mediated amplification

61 were tested by the TVQ assay, and the Aptima T. vaginalis (ATV) assay was performed using clinician-c

62 dates the clinical performance of the Aptima T. vaginalis assay for screening asymptomatic and sympto

63 Archived T. vaginalis isolates from the enrollment visits of 355

64 T. vaginalis infection in HIV-endemic areas, T. vaginalis control may have a substantial impact on pr

65 th care professionals can consider TMA-based T. vaginalis screening for a wide age range of patients;

66 re we describe the performance of the new BD T. vaginalis Qx (TVQ) amplified DNA assay, which can be

67 emi-conservative genomic arrangement between T. vaginalis isolates.

68 nfection, as well as the association between T. vaginalis infection and increased transmission of and

69 We concluded that the interaction between T. vaginalis and hVECs is both cell specific (limited to

70 4 (55%) were introital, were tested for both T. vaginalis DNA and viable microorganisms using the 5'

71 (ii) Activation of local immune cells by T. vaginalis in the presence of infectious HIV-1 might l

72 nd relative light unit (RLU) data yielded by T. vaginalis ASR.

73 fe, aluminum hydroxide-adjuvanted whole-cell T. vaginalis vaccine for efficacy in a BALB/c mouse mode

74 A whole-cell T. vaginalis vaccine was administered subcutaneously to

75 Together, these data indicate that chronic T. vaginalis infections may result in TvMIF-driven infla

76 In all comparisons, T. vaginalis PCR performed better than routine diagnosti

77 us and Neisseria gonorrhoeae with concurrent T. vaginalis infection.

78 mplification test (NAAT) were used to detect T. vaginalis.

79 The mean age of women with detectable T. vaginalis (30.6) was significantly higher than those

80 In females with detectable T. vaginalis, codetection of Chlamydia trachomatis and N

81 tter than wet mount (P = 0.004) and detected T. vaginalis in samples that required 48 to 72 h of incu

82 ated Aptima T. vaginalis assay for detecting T. vaginalis in 1,025 asymptomatic and symptomatic women

83 eement between PCR and culture for detecting T. vaginalis.

84 nge of pathogenic properties among different T. vaginalis strains, all strains show strict contact-de

85 d among the 68 isolates, revealing a diverse T. vaginalis population.

86 cDNA encoding T. vaginalis PNP was isolated by complementation of an E

87 er, contrary to that typical for eukaryotes, T. vaginalis spliceosomal snRNAs lack a cap and may cont

88 start site of transcription in all examined T. vaginalis genes.

89 All examined T. vaginalis introns have a highly conserved 12-nt 3' sp

90 taining 5' untranslated regions of expressed T. vaginalis genes was searched for overrepresented DNA

91 ifferent dsRNA molecules obtained from a few T. vaginalis isolates has suggested that more than one v

92 The presence of CD4(+) T cells following T. vaginalis infection can potentially increase suscepti

93 .74 (95% confidence interval, 1.25-6.00) for T. vaginalis-positive cases.

94 .1% for C. glabrata; and 96.5% and 95.1% for T. vaginalis Sensitivities and specificities were simila

95 for VVC due to Candida glabrata, and 10% for T. vaginalis Sensitivity and specificity estimates for t

96 is a new point-of-care diagnostic assay for T. vaginalis that uses an immunochromatographic capillar

97 extraurogenital sources into assessment for T. vaginalis detection may identify additional symptomat

98 Aptima Trichomonas vaginalis assay; ATV) for T. vaginalis were compared with the Affirm VPIII Trichom

99 VVC, and a composite of NAAT and culture for T. vaginalis The prevalences of infection were similar f

100 eplacement technology has been developed for T. vaginalis.

101 > or =2.0 and < or =1.5 were established for T. vaginalis-positive and -negative cutoffs, respectivel

102 netic markers with clinical implications for T. vaginalis infections.

103 Until a NAAT for T. vaginalis is commercially available, a stepwise appro

104 Vaginal-swab specimens were obtained for T. vaginalis culture, wet mount, and rapid testing.

105 I agents) and 26.1% were solely positive for T. vaginalis (P < 0.0002 versus C. trachomatis).

106 Fifty-one women (38%) screened positive for T. vaginalis at baseline.

107 N. gonorrhoeae, 26 (5.2%) were positive for T. vaginalis, and 47 (9.5%) were positive for M. genital

108 Overall, 5.1% of subjects were positive for T. vaginalis.

109 total samples tested, 6.6% were positive for T. vaginalis.

110 owever, first-void urine detection rates for T. vaginalis and C. trachomatis within this age demograp

111 matic or symptomatic, should be screened for T. vaginalis.

112 hral swab and first-void urine screening for T. vaginalis within a regional health care system was pe

113 ssay in urethral swabs, urine, and semen for T. vaginalis detection in male sexual partners of women

114 vely from both men and women were tested for T. vaginalis DNA with both the FRET-based assay and a pr

115 d be evaluated with more-sensitive tests for T. vaginalis, preferably NAATs, if microscopy is negativ

116 ening asymptomatic and symptomatic women for T. vaginalis infection.

117 e amplified the beta-fructofuranosidase from T. vaginalis cDNA and cloned it into an Escherichia coli

118 binding of T. foetus to BVECs; the LPG from T. vaginalis and a variety of other glycoconjugates did

119 we have isolated an Inr-binding protein from T. vaginalis.

120 A lytic factor (LF) was purified from T. vaginalis, and the molecular characteristics of LF we

121 Furthermore, T. vaginalis LPG (but not LPG from Tritrichomonas foetus

122 Combined-gender T. vaginalis detection rate (9.1%) was significantly gre

123 cquired STIs included chlamydia, gonorrhoea, T. vaginalis and syphilis with rapid plasma reagin >/=1:

124 and 0.24% for C. trachomatis/N. gonorrhoeae/T. vaginalis and highest in women <30 years old.

125 rachomatis/N. gonorrhoeae and N. gonorrhoeae/T. vaginalis, and 0.24% for C. trachomatis/N. gonorrhoea

126 High T. vaginalis prevalence in all age groups suggests that

127 Higher T. vaginalis prevalence in women of >40 years is probabl

128 st levels observed in those with the highest T. vaginalis loads.

129 The highest T. vaginalis prevalence was in women >/= 40 years old (>

130 Eight DRP homologues [T. vaginalis DRPs (TvDRPs)], which can be grouped into 3

131 However, T. vaginalis is disproportionality under studied, especi

132 (i) T. vaginalis disruption of urogenital epithelial monolay

133 ed daily with a light microscope to identify T. vaginalis.

134 We show that 6mA in T. vaginalis is associated with silencing when present o

135 d detect beta-fructofuranosidase activity in T. vaginalis cell lysates.

136 bacteria, in some proteobacteria and also in T. vaginalis, a Type II amitochondriate protist.

137 etic analysis and assess the role of AP65 in T. vaginalis adherence, we silenced expression of ap65 u

138 ce of a plasminogen-binding alpha-enolase in T. vaginalis.

139 o both double and single Inr motifs found in T. vaginalis genes and that binding requires the conserv

140 emonstrate that the conserved motif found in T. vaginalis protein-encoding genes is an Inr promoter e

141 , catalyzing the first step of glycolysis in T. vaginalis, is different from that of the enzyme perfo

142 sms for the regulation of cysteine levels in T. vaginalis, we have characterized enzymes of the merca

143 e (5mC), is the main DNA methylation mark in T. vaginalis Genome-wide distribution of 6mA reveals tha

144 owed divergence of the vaginal microbiota in T. vaginalis-infected and T. vaginalis-uninfected patien

145 hypothesized that the vaginal microbiota in T. vaginalis-infected women differs from that in T. vagi

146 be grouped into 3 subclasses, are present in T. vaginalis.

147 biotic Trichomonasvirus, highly prevalent in T. vaginalis clinical isolates, is sensed by the human e

148 Core promoters in T. vaginalis appear to consist solely of a highly conser

149 demonstrate antisense RNA gene silencing in T. vaginalis to study the contribution of specific genes

150 aginalis-infected women differs from that in T. vaginalis-uninfected women.

151 median of 566 days, there were 806 incident T. vaginalis infections (23.6/100 person-years), and 265

152 A control strategy that includes T. vaginalis screening in nonclinical settings and rapid

153 Increased T. vaginalis detection was derived from female urine spe

154 r (kbp), double-stranded RNA virus infecting T. vaginalis.

155 fect on mammalian PNPs, was shown to inhibit T. vaginalis PNP with a K(is) of 2.3 microM by competing

156 nal leukocytosis, and recurrent (vs initial) T. vaginalis infection, with the lowest levels observed

157 ools and approaches available to interrogate T. vaginalis biology, with an emphasis on recent advance

158 This warrants a more thorough review of male T. vaginalis incidence.

159 Our data reveal a complex structure, named T. vaginalis lipoglycan (TvLG), that differs markedly fr

160 ron of P270 was evident among virus-negative T. vaginalis isolates or virus-negative progeny trichomo

161 A total of 38.1% of T. vaginalis-positive pharyngeal specimens were derived

162 Changes in MST activity of T. vaginalis in response to variation in the supply of e

163 act in the surface expression of adhesins of T. vaginalis organisms.

164 Steady-state kinetic analysis of T. vaginalis PNP-catalyzed reactions gave K(m)'s of 31.5

165 We have shown an association of T. vaginalis with basement membrane extracellular matrix

166 of hybridomas that inhibited the binding of T. vaginalis organisms to immobilized FN was identified.

167 the incidence and increased the clearance of T. vaginalis infection and induced both systemic and loc

168 Coincubation of T. vaginalis isolates with acutely HIV-1-infected periph

169 , accurate, and high-throughput detection of T. vaginalis and may prove useful in clinical settings a

170 richomonosis was defined as the detection of T. vaginalis by direct microscopy and/or culture from ei

171 reported in females, TMA-based detection of T. vaginalis can be a routine constituent within a compr

172 xisting PCR method for specific detection of T. vaginalis DNA into a rapid real-time PCR assay based

173 a sensitive PCR assay, reliable detection of T. vaginalis in male partners required multiple specimen

174 ive and specific PCR assays for detection of T. vaginalis in urine, a noninvasive specimen, and devel

175 he exclusive use of urine-based detection of T. vaginalis is not appropriate in women.

176 to evaluate urine-based PCR for detection of T. vaginalis using a combined reference standard of wet

177 PCR-based detection of T. vaginalis using vaginal specimens may provide an alte

178 d the BD MAX CT/GC/TV assay for detection of T. vaginalis was determined.

179 ng vaginal swab samples for the detection of T. vaginalis was developed to add T. vaginalis infection

180 hniques in urine specimen-based detection of T. vaginalis was highly sensitive and revealed a prevale

181 l and cervical specimen-derived detection of T. vaginalis within African American majority geographic

182 d amplification (TMA) assay for detection of T. vaginalis.

183 The diagnosis of T. vaginalis infection by PCR is a sensitive and specifi

184 er culture or wet mount for the diagnosis of T. vaginalis infections.

185 can be expected to improve the diagnosis of T. vaginalis, especially where microscopy and culture ar

186 lphaMPP and betaMPP before the divergence of T. vaginalis and mitochondria-bearing lineages.

187 The effect of T. vaginalis isolates on HIV-1 passage through polarized

188 t to the monolayer disruption, the effect of T. vaginalis on HIV-1 replication was not isolate depend

189 ess, surface-associated glycolytic enzyme of T. vaginalis.

190 and may be an important virulence factor of T. vaginalis mediating the destruction of host cells and

191 ndicate a role for a TvDRP in the fission of T. vaginalis hydrogenosomes, similar to that described f

192 Cluster analysis revealed 2 unique groups of T. vaginalis-infected women.

193 The incidence of T. vaginalis infection is high among adolescent women; u

194 norrhoeae PCR assay allowed incorporation of T. vaginalis PCR diagnosis into routine clinical testing

195 F-dAdo and F-Ade exert strong inhibition of T. vaginalis growth with estimated IC(50) values of 106

196 rrying out studies to identify inhibitors of T. vaginalis PNP (TvPNP), we discovered that the nontoxi

197 ng a single, agar-cloned clinical isolate of T. vaginalis, confirming the natural capacity for concur

198 Different clinical isolates of T. vaginalis caused damage to cultured cells at differen

199 ixty-eight historical and recent isolates of T. vaginalis were sampled from the American Type Culture

200 s strains, from 4 other clinical isolates of T. vaginalis.

201 ying and treating females with low levels of T. vaginalis infection (before they become wet mount pos

202 used to screen a cDNA expression library of T. vaginalis.

203 The kinetic mechanism of T. vaginalis PNP-catalyzed reactions, determined by prod

204 to the pathogenesis and disease outcomes of T. vaginalis infections of the human genital mucosa.

205 death may be involved in the pathogenesis of T. vaginalis infection in vivo, may have important impli

206 ever having used a condom were predictive of T. vaginalis infection.

207 croscopy and culture and for the presence of T. vaginalis DNA by specific PCR of vaginal and urine sp

208 Pretreatment of T. vaginalis with metronidazole or periodate abolished t

209 The prevalence of T. vaginalis in this sample was 23.4% (105 of 449) by th

210 The prevalence of T. vaginalis infection before HIV infection was 11.3% in

211 Given the high prevalence of T. vaginalis infection in HIV-endemic areas, T. vaginali

212 Thus, prevalence of T. vaginalis infection in men is underestimated if only

213 ettings with a moderately high prevalence of T. vaginalis infection, particularly when microscopy is

214 The prevalence of T. vaginalis was 18.8% overall and 8.8% in the 307 wet-m

215 Treatment and prevention of T. vaginalis infection could reduce HIV-1 risk in women.

216 hat GAPDH is a surface-associated protein of T. vaginalis with alternative functions.

217 entify a fibronectin (FN)-binding protein of T. vaginalis.

218 Given the significant rate of T. vaginalis detection, with age distribution analogous

219 rt addressing the differential regulation of T. vaginalis genes immediately upon contact with VECs.

220 The derived amino acid sequence of T. vaginalis LDH (TvLDH) was found to be more closely re

221 recently completed draft genome sequence of T. vaginalis provides an invaluable resource to guide mo

222 The stability of T. vaginalis DNA in 40 urine samples was assessed by sto

223 Overall, there was better stability of T. vaginalis DNA when specimens were stored at 4 degrees

224 netic diversity, and population structure of T. vaginalis.

225 tified an abundant protein on the surface of T. vaginalis EVs, 4-alpha-glucanotransferase (Tv4AGT), a

226 rate from other facilities exceeded that of T. vaginalis (7.2%; P = 0.004).

227 thesis of GAPDH by antisense transfection of T. vaginalis gave lower levels of organisms bound to FN

228 nt efforts in the diagnosis and treatment of T. vaginalis in women and men, especially in countries w

229 atural history, and response to treatment of T. vaginalis infection in adolescent women.

230 Treatment of T. vaginalis T016 with >/=20 mM 1,4-diamino-2-butanone (

231 Here, we review the existing data on T. vaginalis surface proteins and summarize some of the

232 rom extraurogenital sources, with a focus on T. vaginalis.

233 hibition of ornithine decarboxylase (ODC) on T. vaginalis.

234 An optimal analytical sensitivity of one T. vaginalis organism per PCR was achieved.

235 ions with C. trachomatis, N. gonorrhoeae, or T. vaginalis (women only) detected during 4 scheduled re

236 gnoses of C. trachomatis, N. gonorrhoeae, or T. vaginalis infections should return in 3 months for re

237 detect N. gonorrhoeae and C. trachomatis (or T. vaginalis if utilized), there is no US Food and Drug

238 Moreover, 2 of these other T. vaginalis isolates are concurrently infected by strai

239 Overall, T. vaginalis, C. trachomatis, and N. gonorrhoeae prevale

240 The trichomonad parasite T. vaginalis causes one of the most common non-viral sex

241 levels were lower in females with a positive T. vaginalis antigen test result, a vaginal pH >4.5, vag

242 N. gonorrhoeae infection overall, a positive T. vaginalis ASR result was a better predictor of concom

243 ected-patient status was defined as positive T. vaginalis test results by at least 2 assays.

244 The increased rate of positive T. vaginalis ASR results was observed in both point-of-c

245 While positive T. vaginalis findings via direct saline preparation did

246 an interview and a pelvic exam, four primary T. vaginalis tests (wet mount, culture, a rapid test, an

247 found that T. vaginalis secretes a protein, T. vaginalis macrophage migration inhibitory factor (TvM

248 the presence of clinical symptoms or repeat T. vaginalis infections with TVV+ isolates (P = .14 and

249 the presence of a 5.5-kb double-stranded RNA T. vaginalis virus (TVV) was assessed.

250 Highly sensitive T. vaginalis molecular ASR not only transcends issues of

251 The short T. vaginalis PFK shares a most recent common ancestor wi

252 re, we biochemically characterize the single T. vaginalis Tgs (TvTgs) encoded in its genome and demon

253 STI phenotype reflected detection of solely T. vaginalis (54.2% of all health care encounters that r

254 to identify a simple method for stabilizing T. vaginalis DNA in urine samples that could be easily a

255 Finally, we demonstrate that T. vaginalis EV uptake is dependent on host cell cholest

256 ic and phylogenetic analyses determined that T. vaginalis population structure is strongly influenced

257 We have found that T. vaginalis mRNAs are protected by a 5' cap structure,

258 We have found that T. vaginalis secretes a protein, T. vaginalis macrophage

259 It has been reported that T. vaginalis does not grow on sucrose.

260 We show that T. vaginalis EVs interact with glycosaminoglycans on the

261 r intracellular redox buffer by showing that T. vaginalis contains high levels of cysteine ( approxim

262 The T. vaginalis alpha-actinin amino acid sequence and the s

263 The T. vaginalis LPG triggered interleukin 8 (IL-8), which p

264 The T. vaginalis-specific probe contains a 5'-fluorescein (5

265 , no significant difference was noted in the T. vaginalis detection rates (8.9 and 8.6%, P = 0.85).

266 ding in other PPi-PFKs were conserved in the T. vaginalis enzyme.

267 5 A/B, which target different regions in the T. vaginalis genome, and seven were determined to be fal

268 Nevertheless, the T. vaginalis genome contains some 11 putative sucrose tr

269 Comparison of the T. vaginalis alpha-actinin epitopes with proteins in dat

270 ales (24.7 years) was lower than that of the T. vaginalis-infected females (mean, 30.1 years; P < 0.0

271 surface glycoconjugate of the parasite, the T. vaginalis lipophosphoglycan (LPG).

272 studies indicate that it interacts with the T. vaginalis RNAP II large subunit C-terminal domain.

273 Thus, T. vaginalis PNP (TvPNP) functions in the reverse direct

274 results suggest that TVV may be commensal to T. vaginalis.

275 nted with symptoms of vaginitis, exposure to T. vaginalis, or multiple sexual partners.

276 action to alpha-actinin suggests exposure to T. vaginalis.

277 with the hypothesis that drug resistance to T. vaginalis resulted from a single or very few mutation

278 ng host inflammatory and immune responses to T. vaginalis are poorly understood.

279 ion prevalences were 1.3% for C. trachomatis/T. vaginalis, 0.61% for C. trachomatis/N. gonorrhoeae an

280 and the increased risk for HIV transmission, T. vaginalis infection should be reconsidered for inclus

281 adhesins between control versus DAB-treated T. vaginalis parasites.

282 Equally noteworthy was that DAB-treated T. vaginalis with enhanced adherence did not possess the

283 After treatment, T. vaginalis DNA was undetectable within 2 weeks in all

284 the four primary tests was considered a true T. vaginalis-positive result.

285 Of 355 T. vaginalis isolates tested for TVV, T. vaginalis isolates tested for TVV, the prevalence was

286 A key difference between the two T. vaginalis sequences was that Arg91 of MDH, known to b

287 itivity for every additional day delay until T. vaginalis was first detected in cultures (odds ratio

288 ith no difference between urethral and urine T. vaginalis detection (P = 0.53).

289 ence and cytotoxicity were not observed when T. vaginalis was exposed to human vaginal fibroblasts or

290 locations were significantly associated with T. vaginalis infection.

291 se, and HIV-infection status associated with T. vaginalis infection.

292 VCU-M1, which is also associated with T. vaginalis.

293 Coincubation with T. vaginalis isolates induced disruption of monolayer in

294 All sequences were colinear with T. vaginalis gap1 and shared with it as a synapomorphy a

295 epithelial cells or cell lines cultured with T. vaginalis was measured by monitoring transepithelium

296 A in vaginal fluids from women infected with T. vaginalis and uninfected controls.

297 Sera from patients infected with T. vaginalis are reactive to TvMIF, especially in males.

298 om 838 women, 116 of whom were infected with T. vaginalis, were analyzed.

299 issues following intravaginal infection with T. vaginalis but were not seen in uninfected mice.

300 A total of 85.7% of males with T. vaginalis-positive pharyngeal collections indicated s

301 This rate was higher than those seen with T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), a